Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acceleron Pharma has been selected to receive a Biotech Investment Award from the Multiple Myeloma Research Foundation to support the research and development of ACE-011, a novel bone forming agent, for the treatment of multiple myeloma.
Subscribe to our email newsletter
The multiple dose study will be conducted in healthy, post-menopausal women. Subjects will receive four monthly subcutaneous doses of either ACE-011 or placebo. The primary objective of the study is to assess the safety, tolerability and pharmacokinetics of ACE-011. The pharmacodynamic effects of ACE-011 on bone will also be measured. In addition, Acceleron has announced that it started a randomized, double-blind, placebo-controlled multiple ascending dose study of ACE-011.
Matthew Sherman, chief medical officer of Acceleron, said: “We are excited to start this study with ACE-011 and expect to begin additional studies with this compound later in 2008 for the treatment of cancer and cancer-related bone loss.”